Sawai Chalks Up More Than A Dozen Launches
Follows Approvals From Japan's MHLW Earlier This Year
Sawai has followed-up on a raft of approvals announced earlier this year with launch plans, including for the first generics of Daiichi Sankyo’s Memary (memantine hydrochloride) Alzheimer’s disease treatment in three presentations.
